GBT - GBT STOCK NEWS

Global Blood Therapeutics (GBT) has received Marketing Authorization from the European Commission for Oxbryta (voxelotor), the first sickle hemoglobin polymerization inhibitor approved in Europe. This once-daily oral therapy treats hemolytic anemia in sickle cell disease (SCD) patients aged 12 and older, either alone or with hydroxyurea. Oxbryta improves hemoglobin levels and reduces hemolysis, potentially transforming SCD management. The approval follows a positive review by the Committee for Medicinal Products for Human Use, based on significant results from the Phase 3 HOPE study.

Global Blood Therapeutics (GBT) announced on February 1, 2022, the granting of stock options and restricted stock units to 21 new employees. The total grants include options for 33,290 shares at an exercise price of $29.33 and restricted units for 80,100 shares, all awarded under the Amended and Restated 2017 Inducement Equity Plan. This decision aligns with NASDAQ Listing Rule 5635(c)(4), aiming to incentivize new hires as part of the company's strategy in developing treatments for sickle cell disease.

Global Blood Therapeutics (GBT) announced that Oxbryta^® (voxelotor) tablets for oral suspension, a new once-daily dosage form, is now available in the U.S. This approval expands the use of Oxbryta to treat sickle cell disease (SCD) in children aged 4–12 years. Oxbryta directly targets sickle hemoglobin polymerization, improving oxygen delivery and mitigating the effects of SCD. GBT has also launched the GBT Source Solutions program to support patients with access and education regarding their treatment.

Global Blood Therapeutics (GBT) announced the grant of stock options and restricted stock units to 10 new employees on January 1, 2022. The awards include options for 15,225 shares at an exercise price of $29.27 and 41,830 shares in restricted stock units, under GBT's Amended and Restated 2017 Inducement Equity Plan. These grants comply with NASDAQ Listing Rule 5635(c)(4) as inducements for employment.

GBT is focused on transforming treatments for sickle cell disease (SCD), with products like Oxbryta and ongoing development programs.

Global Blood Therapeutics, Inc. (GBT) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 11:15 a.m. E.T. The event will be streamed live on GBT's website, with an archived replay available for one month afterward. GBT is focused on developing treatments for sickle cell disease (SCD) and has introduced the FDA-approved Oxbryta® (voxelotor) to address this condition. The company's pipeline includes inclacumab and GBT021601, alongside ongoing drug discovery efforts.

Global Blood Therapeutics (GBT) announced that the FDA granted accelerated approval for Oxbryta^® (voxelotor) tablets for treating sickle cell disease (SCD) in children aged 4 to under 12. This expands the drug's previously approved use for patients aged 12 and older. The approval includes a new dispersible tablet formulation to ease administration. The FDA's decision is based on Phase 2a study data showing the drug improves hemoglobin levels and reduces red blood cell destruction. GBT aims to address a significant unmet need in pediatric SCD treatment.

Global Blood Therapeutics (GBT) announced that the European Medicines Agency's CHMP has adopted a positive opinion for marketing authorization of **Oxbryta** (voxelotor) for treating hemolytic anemia due to **sickle cell disease** in patients aged 12 and older. A decision from the European Commission is expected in Q1 2022. Oxbryta is the first oral therapy in Europe that inhibits sickle hemoglobin polymerization, addressing significant health complications associated with SCD. Clinical trials demonstrated meaningful increases in hemoglobin levels and reduced hemolysis with Oxbryta treatment.

Global Blood Therapeutics (GBT) announced the pricing of $300 million in Convertible Senior Notes due 2028, increased from an initial $250 million. The offering is aimed at qualified institutional buyers, and net proceeds are estimated at approximately $290.4 million. The notes bear a 1.875% interest rate, maturing on December 15, 2028, with an initial conversion rate set at 31.4985 shares per $1,000 principal amount. Proceeds will fund capped call transactions, Oxbryta commercialization, and clinical developments.

Global Blood Therapeutics (GBT) announced a private offering of $250 million in Convertible Senior Notes due 2028, with an option to purchase an additional $37.5 million. Interest will be paid semi-annually, and the notes can be converted into cash, shares, or both. GBT plans to use proceeds for capped call transactions and to support commercialization and clinical development of Oxbryta and other product candidates. The offering is limited to qualified institutional buyers and is subject to market conditions.